Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   12:56:37 AM EDT
961.93
-4.37 (-0.45%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)105.59B
Current PE26.71
Forward PE 21.31
2yr Forward PE 20.27
See more stats
Estimates Current Quarter
Revenue$3.22 Billion
Adjusted EPS$10.04
See more estimates
10-Day MA$964.62
50-Day MA$958.56
200-Day MA$846.24
See more pivots

Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 13450

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.